Valuation: Ipsen

Market Cap 13.27B 15.35B 12.4B 11.37B 21.39B 1,460B 21.73B 145B 57.08B 732B 57.63B 56.37B 2,420B P/E 2026 *
13.4x
P/E 2027 * 14.2x
Enterprise Value 11.89B 13.74B 11.1B 10.18B 19.15B 1,308B 19.46B 130B 51.12B 656B 51.61B 50.48B 2,167B EV / Sales 2026 *
2.65x
EV / Sales 2027 * 2.4x
Free-Float
40.65%
Yield 2026 *
0.95%
Yield 2027 * 0.95%
1 day+0.03%
1 week-4.01%
Current month-4.01%
1 month-4.29%
3 months-5.64%
6 months+17.58%
Current year+35.21%
1 week 153.1
Extreme 153.1
165
1 month 153.1
Extreme 153.1
171.8
Current year 116
Extreme 116
176.6
1 year 105.6
Extreme 105.6
176.6
3 years 88.05
Extreme 88.05
176.6
5 years 77.28
Extreme 77.28
176.6
10 years 35.52
Extreme 35.52
176.6
Manager TitleAgeSince
Chief Executive Officer 59 01/07/2020
Chief Executive Officer 57 01/01/2020
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 61 30/08/2005
Chairman 68 22/11/2010
Director/Board Member 69 01/06/2012
Change 5-day change 1-year change 3-year change Capi.($)
-0.74%-4.01% - - 15.3B
-0.69%+3.21%+85.02%+161.13% 1,062B
+0.55%+0.52%+50.23%+48.87% 619B
+0.54%-2.17%+23.45%+63.30% 431B
+0.71%+3.87%+47.45%+38.68% 358B
+0.64%-0.49%+35.39%+40.21% 293B
+0.39%-5.83%+8.64%+9.28% 247B
+1.46%+6.74%+44.41%+62.54% 219B
+3.92%-0.46%-1.21%-44.09% 200B
+1.92%+2.80%+21.38%+65.94% 162B
Average +1.05%-1.90%+34.97%+49.54% 399.14B
Weighted average by Cap. +0.59%-0.83%+48.43%+75.78%

Financials

2026 *2027 *
Net sales 4.49B 5.19B 4.19B 3.84B 7.23B 494B 7.34B 49.15B 19.29B 247B 19.47B 19.05B 818B 4.57B 5.29B 4.27B 3.92B 7.37B 503B 7.49B 50.11B 19.67B 252B 19.86B 19.42B 834B
Net income 1.01B 1.17B 946M 868M 1.63B 111B 1.66B 11.1B 4.36B 55.86B 4.4B 4.3B 185B 961M 1.11B 897M 823M 1.55B 106B 1.57B 10.53B 4.13B 52.98B 4.17B 4.08B 175B
Net Debt -1.39B -1.6B -1.29B -1.19B -2.23B -153B -2.27B -15.19B -5.96B -76.47B -6.02B -5.89B -253B -2.31B -2.67B -2.16B -1.98B -3.72B -254B -3.78B -25.3B -9.93B -127B -10.03B -9.81B -421B
Logo Ipsen
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (69.2%); - neuroscience (20.3%); - rare diseases (10.5%). At the end of 2025, the group had 7 research and development centers located in France (2), the United Kingdom (2), China (2) and Ireland, and 5 manufacturing sites worldwide. Net sales are distributed geographically as follows: France (8%), Europe (31.7%), the United States (32.9%), North America (2.2%) and other (25.2%).
Employees
5,535
Date Price Change Volume
08/08/26 EUR 160.50 -0.74% 1
06/08/26 EUR 161.40 +1.51% 624
05/08/26 EUR 159.00 +1.27% 36,155
04/08/26 EUR 157.00 +2.55% 1,209
03/08/26 EUR 153.10 -8.43% 452
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
161.90EUR
Average target price
163.87EUR
Spread / Average Target
+1.21%

Quarterly revenue - Rate of surprise